Details
In this report, we describe the concomitant use of drugs that interact with Paxlovid (nirmatrelvir/ritonavir), a co-packaged oral drug product consisting of nirmatrelvir and ritonavir, among patients treated with nirmatrelvir/ritonavir and patients with an outpatient diagnosis of COVID-19. The main purpose is to estimate the proportion of the nirmatrelvir/ritonavir-eligible population (i.e., adults who are at high risk for development of severe COVID-19) or nirmatrelvir/ritonavir users who are taking concomitant medications that have drug-drug interactions (DDI) with nirmatrelvir/ritonavir.
The study period includes data from December 22, 2021 to December 31, 2022. We distributed this request to six Sentinel Rapid COVID-19 Data Partners on April 3, 2023.